Brensocatib

FDA Drug Profile — Brinsupri

Drug Details

Generic Name
Brensocatib
Brand Names
Brinsupri
Application Number
NDA217673
Sponsor
Insmed Incorporated
NDC Codes
2
Dosage Forms
TABLET
Routes
ORAL
Active Ingredients
BRENSOCATIB

Indications and Usage

1 INDICATIONS AND USAGE BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older. BRINSUPRI is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric patients 12 years of age and older. ( 1 )